STOCK TITAN

Kiora Pharmaceuticals: Alyeska reports 4.99% ownership

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Kiora Pharmaceuticals, Inc. (KPRX) is the issuer in an amended beneficial-ownership report in which Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh each report the same 220,776-share position in common stock issuable upon warrant exercise, equal to 4.99% of the class as of September 30, 2026.

The position is held by Alyeska Master Fund, L.P.; Alyeska Investment Group, as investment manager, exercises voting and investment control. Parekh, the investment group's Chief Executive Officer, may be deemed a beneficial owner and disclaims beneficial ownership. The reporting persons hold warrants exercisable for 596,854 shares, but a beneficial ownership limitation permits exercise of only 220,776 warrant shares. Kiora had 4,424,387 common shares outstanding as of August 7, 2026.

Beneficially owned shares 220,776 shares Reported by each reporting person as of September 30, 2026; shares are issuable upon warrant exercise.
Percent of class 4.99% Reported ownership percentage as of September 30, 2026.
Warrants exercisable for 596,854 shares Warrants held by the reporting persons, subject to a beneficial ownership limitation.
Common shares outstanding 4,424,387 shares As of August 7, 2026.
beneficial ownership limitation technical
"beneficial ownership limitation that prohibits exercise"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
shared voting power technical
"Shared voting power 220,776.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power technical
"Shared dispositive power 220,776.00"
investment control technical
"exercises voting and investment control over the shares"
warrants financial
"shares of Common Stock issuable upon exercise of warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KPRX shares did the reporting persons report owning?

Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh each reported beneficial ownership of 220,776 shares issuable upon warrant exercise, or 4.99% of the class, as of September 30, 2026. The position is held by Alyeska Master Fund, L.P.; Alyeska Investment Group exercises voting and investment control.

How does the KPRX warrant ownership limit work?

The warrants are exercisable for 596,854 shares, but a beneficial ownership limitation prohibits exercise to the extent it would cause the holder's beneficial ownership to exceed 4.99% of outstanding common stock. Based on 4,424,387 shares outstanding as of August 7, 2026, the limitation permits exercise of 220,776 warrant shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





49721T507

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Alyeska Investment Group, L.P.
Signature:Jason Bragg
Name/Title:Jason Bragg | Chief Financial Officer
Date:11/16/2026
Alyeska Fund GP, LLC
Signature:Jason Bragg
Name/Title:Jason Bragg | Chief Financial Officer
Date:11/16/2026
Anand Parekh
Signature:Anand Parekh
Name/Title:Anand Parekh | Self
Date:11/16/2026
Exhibit Information

As of September 30, 2026, the Reporting Persons beneficially own 220,776 shares of Common Stock issuable upon exercise of warrants. The Reporting Persons hold warrants exercisable for 596,854 shares; however, such warrants contain a beneficial ownership limitation that prohibits exercise to the extent it would cause the holder's beneficial ownership to exceed 4.99% of the outstanding Common Stock. Based on 4,424,387 shares of Common Stock outstanding (per the Form 10-Q dated August 7, 2026), the 4.99% limitation permits exercise of only 220,776 warrant shares. Position held by Alyeska Master Fund, L.P. Alyeska Investment Group, L.P., as investment manager, exercises voting and investment control over the shares held by Alyeska Master Fund, L.P. Anand Parekh, as Chief Executive Officer of Alyeska Investment Group, L.P., may be deemed the beneficial owner of such shares. Mr. Parekh disclaims beneficial ownership of such shares. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Keep reading